ACADIA director exercises RSUs, gets new options

ACADIA Pharmaceuticals director Edmund Harrigan reported compensation-related equity activity, not open-market trading.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ACADIA Pharmaceuticals director Edmund Harrigan reported compensation-related equity activity, not open-market trading. On May 29, 2026, he exercised restricted stock units into 8,107 shares of common stock, bringing his direct common stock holdings to 43,148 shares.

He also received new awards on the same date: 9,311 restricted stock units, each representing a right to one share of common stock, and 16,004 director stock options with a $21.66 exercise price expiring on May 28, 2036. The new RSUs and options vest over roughly one year or until the next annual stockholders’ meeting, aligning his compensation with shareholder outcomes.

Insider Trade Summary

8,107 shares exercised/converted

Exercise 4 txns

Insider HARRIGAN EDMUND

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	8,107	$0.00	$0.00
Grant/Award	Director Stock Options (Right to Buy)	16,004	$0.00	$0.00
Grant/Award	Restricted Stock Units	9,311	$0.00	$0.00
Exercise	Common Stock	8,107	$0.00	$0.00

Holdings After Transaction: Director Stock Options (Right to Buy) — 16,004 contracts (Direct); Restricted Stock Units — 9,311 contracts (Direct); Common Stock — 43,148 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
F3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
F4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

Key Figures

RSUs exercised into common stock: 8,107 shares Common shares held after transactions: 43,148 shares New restricted stock units granted: 9,311 RSUs +3 more

6 metrics

RSUs exercised into common stock 8,107 shares Restricted stock units converted to common on May 29, 2026

Common shares held after transactions 43,148 shares Direct common stock holdings following May 29, 2026 activity

New restricted stock units granted 9,311 RSUs Each RSU represents a right to one common share

New director stock options granted 16,004 options Options on common stock granted May 29, 2026

Option exercise price $21.66 per share Conversion or exercise price for new director stock options

Option expiration date May 28, 2036 Expiration of newly granted director stock options

Key Terms

Restricted Stock Units, Director Stock Options (Right to Buy), vested in full, vest quarterly, +1 more

5 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Director Stock Options (Right to Buy) financial

"Director Stock Options (Right to Buy) with an exercise price of 21.6600."

vested in full financial

"The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held."

vest quarterly financial

"The shares subject to each stock option will vest quarterly over one year following the date of grant."

annual meeting of stockholders financial

"The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ACAD director Edmund Harrigan report?

Edmund Harrigan reported equity compensation activity, not market trading. He exercised 8,107 restricted stock units into common stock and received new grants of 9,311 restricted stock units and 16,004 stock options, all tied to his role as a director.

How many ACADIA Pharmaceuticals (ACAD) shares does the director hold after these transactions?

After exercising restricted stock units, Edmund Harrigan directly holds 43,148 shares of ACADIA common stock. This figure reflects his position following the May 29, 2026 transactions and excludes his new unvested restricted stock units and stock options.

What equity awards did the ACAD director receive on May 29, 2026?

On May 29, 2026, the director received 9,311 restricted stock units and 16,004 director stock options. Each restricted stock unit represents a right to one ACADIA common share, and each option allows purchase of one share at a $21.66 exercise price.

What are the vesting terms of the new ACAD restricted stock units and options?

The new restricted stock units vest in full on the earlier of one year from grant or the next annual stockholders’ meeting. The new stock options vest quarterly over one year on the same schedule, aligning vesting with ongoing board service.

What is the exercise price and expiration date of the new ACAD director stock options?

The newly granted director stock options have a $21.66 exercise price per share and expire on May 28, 2036. They vest in quarterly installments over the year following grant, or sooner if the next annual stockholders’ meeting occurs earlier.

Did the ACAD director sell any shares in this Form 4 filing?

No sales were reported. The Form 4 shows only acquisitions through an option or unit exercise and new equity grants. There were no open-market purchases or sales; all activity reflects routine director compensation arrangements in stock and options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/01/2026 - 06:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HARRIGAN EDMUND

(Last)

(First)

(Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		M		8,107	A	⁽¹⁾	43,148	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/29/2026		M			8,107	⁽²⁾	⁽²⁾	Common Stock	8,107	$0	0	D
Director Stock Options (Right to Buy)	$21.66	05/29/2026		A		16,004		⁽³⁾	05/28/2036	Common Stock	16,004	$0	16,004	D
Restricted Stock Units	⁽¹⁾	05/29/2026		A		9,311		⁽⁴⁾	⁽⁴⁾	Common Stock	9,311	$0	9,311	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.

3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.

4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR